Literature DB >> 16608165

Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.

Jason Labutti1, Ian Parsons, Ron Huang, Gerald Miwa, Liang-Shang Gan, J Scott Daniels.   

Abstract

Bortezomib (1) is a potent first-in-class dipeptidyl boronic acid proteasome inhibitor employed in the treatment of patients with relapsed multiple myeloma where the disease is refractory to conventional lines of therapy. The potency of 1 is owed primarily to the presence of the boronic acid moiety, one which is suited to establish a tetrahedral intermediate with the active site N-terminal threonine residue of the proteasome. Hence, deboronation of 1 represents a deactivation pathway for this chemotherapeutic agent. Deboronation of 1 affords a near equal mixture of diastereomeric carbinolamide metabolites (M1/M2) and represents the principal metabolic pathway observed in humans. In vitro results from human liver microsomes and human cDNA-expressed cytochrome P450 enzymes (P450) indicate a role for P450 in the deboronation of 1. Use of 18O-labeled oxygen under controlled atmospheres confirmed an oxidative mechanism in the P450-mediated deboronation of 1, as 18O was found incorporated in both M1 and M2. Chemically generated reactive oxygen species (ROS), such as those generated as byproducts during P450 catalysis, were also found to deboronate 1 resulting in the formation of M1 and M2. Known to undergo efficient redox cycling, P450 2E1 was found to catalyze the deboronation of 1 predominantly to the carbinolamide metabolites M1 and M2, as well as to a pair of peroxycarbinolamides, 2 and 3. The presence of superoxide dismutase (SOD) and catalase prevented the deboronation of 1, thus, supporting the involvement of ROS in the P450 2E1-catalyzed deboronation reaction. The presence of SOD and catalase also protected 1 against P450 3A4-catalyzed deboronation, albeit to a lesser extent. The remaining deboronation activity observed in the P450 3A4 reaction may suggest the involvement of the more conventional activated enzyme-oxidants previously described for P450. Our present findings indicate that the oxidase activity of P450 (i.e., formation of ROS) represents a mechanism of deboronation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608165     DOI: 10.1021/tx050313d

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  14 in total

1.  Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Authors:  Patricia M LoRusso; Karthik Venkatakrishnan; Ramesh K Ramanathan; John Sarantopoulos; Daniel Mulkerin; Stephen I Shibata; Anne Hamilton; Afshin Dowlati; Sridhar Mani; Michelle A Rudek; Chris H Takimoto; Rachel Neuwirth; Dixie-Lee Esseltine; Percy Ivy
Journal:  Clin Cancer Res       Date:  2012-03-06       Impact factor: 12.531

Review 2.  The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Authors:  Robert Z Orlowski
Journal:  Oncology (Williston Park)       Date:  2011-11-15       Impact factor: 2.990

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.

Authors:  Carlyn Rose C Tan; Saif Abdul-Majeed; Brittany Cael; Stefan K Barta
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

4.  Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.

Authors:  Donna E Reece; Dan Sullivan; Sagar Lonial; Ann F Mohrbacher; Gurkamal Chatta; Chaim Shustik; Howard Burris; Karthik Venkatakrishnan; Rachel Neuwirth; William J Riordan; Michael Karol; Lisa L von Moltke; Milin Acharya; Peter Zannikos; A Keith Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-20       Impact factor: 3.333

Review 5.  Molecular recognition with boronic acids-applications in chemical biology.

Authors:  Gillian F Whyte; Ramon Vilar; Rudiger Woscholski
Journal:  J Chem Biol       Date:  2013-06-01

6.  Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.

Authors:  David I Quinn; John Nemunaitis; Jyotsna Fuloria; Carolyn D Britten; Nashat Gabrail; Lorrin Yee; Milin Acharya; Kai Chan; Nadine Cohen; Assen Dudov
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  A computational characterization of boron-oxygen multiple bonding in HN=CH-CH=CH-NH-BO.

Authors:  Joseph D Larkin; Krishna L Bhat; George D Markham; Tony D James; Bernard R Brooks; Charles W Bock
Journal:  J Phys Chem A       Date:  2008-08-15       Impact factor: 2.781

8.  Computational investigation of the oxidative deboronation of boroglycine, H2N-CH2-B(OH)2, Using H2O and H2O2.

Authors:  Joseph D Larkin; George D Markham; Matt Milkevitch; Bernard R Brooks; Charles W Bock
Journal:  J Phys Chem A       Date:  2009-10-15       Impact factor: 2.781

Review 9.  Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.

Authors:  Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

Review 10.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma.

Authors:  Nikki Blosser; Jennifer Jupp; Patrick Yau; Douglas Stewart
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.